CUI JINGRONG JEAN (Chief Scientific Officer) sold 1.4% of their position (11.50K shares) of TURNING POINT THERAPEUTICS, INC. on the open market
Open‑market sale worth $529.4K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 3/27/2020ACC: 0001209191-20-021490
DirectorOfficer10% Owner· Chief Scientific Officer
Since Apr 2019
-11.50K
Net shares
Net seller
$529.4K
Total sold
4
Open market trades
0B · 4S
4
Total transactions
11.50K disposed
Non-Derivative Transactions4
Common Stock
Indirect
Shares
−6.60K
Price / share
$45.37
Trade value
$299.44K
% of position
0.8%
3/26/2020
793.59K→786.99K
Common Stock
Indirect
Shares
−3.05K
Price / share
$46.55
Trade value
$142.07K
% of position
0.4%
3/26/2020
786.99K→783.94K
Common Stock
Indirect
Shares
−1.65K
Price / share
$47.48
Trade value
$78.25K
% of position
0.2%
3/26/2020
783.94K→782.29K
Common Stock
Indirect
Shares
−200.00
Price / share
$48.06
Trade value
$9.61K
% of position
0.0%
3/26/2020
782.29K→782.09K
Total
Net shares
−11.50K
Net value
-$529.37K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 3/26/2020 | S · Sale | −6.60K | $45.37 | $299.44K | 0.8% | 793.59K | 786.99K |
| Common Stock Indirect | 3/26/2020 | S · Sale | −3.05K | $46.55 | $142.07K | 0.4% | 786.99K | 783.94K |
| Common Stock Indirect | 3/26/2020 | S · Sale | −1.65K | $47.48 | $78.25K | 0.2% | 783.94K | 782.29K |
| Common Stock Indirect | 3/26/2020 | S · Sale | −200.00 | $48.06 | $9.61K | 0.0% | 782.29K | 782.09K |
| Total | −11.50K | -$529.37K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned300K
Common Stock
DirectShares owned1M
Total
1M direct·300K indirect1.30M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 300K | Indirect |
| Common Stock | 1M | Direct |
| Total | 1.30M | 1M direct·300K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported